CN101005855A - 治疗由ccr2介导的疾病或紊乱的方法 - Google Patents

治疗由ccr2介导的疾病或紊乱的方法 Download PDF

Info

Publication number
CN101005855A
CN101005855A CNA2005800276608A CN200580027660A CN101005855A CN 101005855 A CN101005855 A CN 101005855A CN A2005800276608 A CNA2005800276608 A CN A2005800276608A CN 200580027660 A CN200580027660 A CN 200580027660A CN 101005855 A CN101005855 A CN 101005855A
Authority
CN
China
Prior art keywords
ccr2
therapeutic agent
mice
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800276608A
Other languages
English (en)
Chinese (zh)
Inventor
P·科尼利厄斯
R·P·格拉杜
R·S·加洛法罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN101005855A publication Critical patent/CN101005855A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA2005800276608A 2004-07-30 2005-07-18 治疗由ccr2介导的疾病或紊乱的方法 Pending CN101005855A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59268304P 2004-07-30 2004-07-30
US60/592,683 2004-07-30

Publications (1)

Publication Number Publication Date
CN101005855A true CN101005855A (zh) 2007-07-25

Family

ID=35207829

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800276608A Pending CN101005855A (zh) 2004-07-30 2005-07-18 治疗由ccr2介导的疾病或紊乱的方法

Country Status (14)

Country Link
US (1) US20090196823A1 (enExample)
EP (1) EP1778285A2 (enExample)
JP (1) JP2008508253A (enExample)
KR (1) KR20080044360A (enExample)
CN (1) CN101005855A (enExample)
AU (1) AU2005268545A1 (enExample)
BR (1) BRPI0513953A (enExample)
CA (1) CA2575612A1 (enExample)
IL (1) IL180675A0 (enExample)
MX (1) MX2007001204A (enExample)
NO (1) NO20070996L (enExample)
RU (1) RU2007103332A (enExample)
WO (1) WO2006013427A2 (enExample)
ZA (1) ZA200700823B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
NZ591471A (en) 2008-08-18 2012-08-31 Pfizer Antibodies to ccr2
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
ES2636679T3 (es) * 2011-06-27 2017-10-06 Université Pierre Et Marie Curie (Paris 6) Péptidos antagonistas de CCR2
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2792837B1 (fr) * 1999-04-29 2001-07-13 Centre Nat Rech Scient Medicaments utiles pour le traitement des troubles de la regulation de la masse adipeuse et des maladies associees aux troubles de la production de leptine
CA2483253A1 (en) * 2002-04-24 2003-11-06 Takeda Pharmaceutical Company Limited Use of compounds having ccr antagonism
CN1871012A (zh) * 2003-07-15 2006-11-29 麦克公司 趋化因子受体活性的7和8元杂环环苯基苄基酰胺调节剂
JP4740151B2 (ja) * 2003-12-18 2011-08-03 インサイト コーポレイション ケモカイン受容体のモジュレーターとしての３‐シクロアルキルアミノピロリジン誘導体

Also Published As

Publication number Publication date
ZA200700823B (en) 2008-10-29
JP2008508253A (ja) 2008-03-21
WO2006013427A2 (en) 2006-02-09
MX2007001204A (es) 2007-03-23
WO2006013427A3 (en) 2006-06-08
US20090196823A1 (en) 2009-08-06
BRPI0513953A (pt) 2008-05-20
EP1778285A2 (en) 2007-05-02
IL180675A0 (en) 2007-06-03
CA2575612A1 (en) 2006-02-09
KR20080044360A (ko) 2008-05-20
AU2005268545A1 (en) 2006-02-09
NO20070996L (no) 2007-04-23
RU2007103332A (ru) 2008-08-10

Similar Documents

Publication Publication Date Title
Carvajal-Vergara et al. Multifunctional role of Erk5 in multiple myeloma
Jeyaseelan et al. Induction of CXCL5 during inflammation in the rodent lung involves activation of alveolar epithelium
Tan et al. LNK promotes granulosa cell apoptosis in PCOS via negatively regulating insulin-stimulated AKT-FOXO3 pathway
ES2275628T3 (es) Uso de un agonista/antagonista de estrogenos para el tratamiento de disfucion sexual femenina.
US20090162286A1 (en) Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions
US20090123456A1 (en) Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
Rossi et al. Hepatic G i signaling regulates whole-body glucose homeostasis
EP1379269B1 (en) Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
KR20030023747A (ko) 인슐린 저항성 증후군의 치료
CN101808642A (zh) 肥大细胞稳定剂治疗肥胖症
Li et al. Prostanoid EP4 agonist L-902,688 activates PPARγ and attenuates pulmonary arterial hypertension
JP7127988B2 (ja) 新規な組成物ならびに慢性閉塞性肺疾患を処置および／または予防する方法
Allen et al. Taxol enhances but does not induce interleukin-1β and tumor necrosis factor-α production
CN1420775A (zh) 鉴定及使用a2b腺苷受体拮抗剂介导哺乳动物细胞增殖的方法
CN101005855A (zh) 治疗由ccr2介导的疾病或紊乱的方法
US20240180921A1 (en) Cdk8/19 inhibitors for the treatment of cytokine storm
Davtyan et al. Hypothalamic proline-rich polypeptide is an oxidative burst regulator
TWI359271B (en) Pharmaceutical composition for insulin resistance
US20060251651A1 (en) Antagonist and agonist which bind to a strong binding site of chemokine receptor
HK1105532A (en) Treatment of ccr2 mediated diseases or disorders
US20140037578A1 (en) IL-25 Treatment of Obesity and Metabolic Disorders
US20060258582A1 (en) Method of treating myelodysplastic syndromes
CN109846879B (zh) 亚胺结构类型雄激素受体拮抗剂及其应用
TW200539864A (en) Oxydecahydronaphthalene modulators of HM74
JP2006510590A (ja) アレルギー及び喘息の処置のためのヒスタミンｈ４受容体モジュレーターの使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105532

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1105532

Country of ref document: HK